Biocytogen/Eucure Biopharma Announce the Completio...
BEIJING, December 7, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen,announced
the completion of first patient dosing for phase I clinical trial of YH004
(anti-4-1BB monoclonal antibody, mAb) (No. YH004002) in Australia...